ImmunoCellular Therapeutics IMUC dropped 59.85% to $1.09 after the company announced positive ICT-107 Phase II study results. Roth Capital downgraded the stock from Buy to Neutral.
Synthetic Biologics SYN plummeted 22.06% to $0.99 after the company priced 11.5 million shares of common stock at $1.00.
XTL Biopharmaceuticals XTLB dropped 17% to $2.49. XTL Biopharmaceuticals shares have dropped 60.00% over the past 52 weeks, while the S&P 500 index has gained 25.56% in the same period.
Sigma Designs SIGM dropped 16.82% to $4.45 on Q3 results. Needham downgraded the stock from Buy to Hold.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in